However, treatment outcomes following immunotherapy was reported to be less effective in patients with EGFR-mutant NSCLC than in those with EGFR wild type NSCLC, based on subgroup analyses of Phase III clinical trials [10]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.